Testing for these gene mutations will ultimately determine the appropriate treatment to go forward with when treating adenocarcinoma; hence, if the K-RAS mutation is present, that would indicate that the anti-EGFR treatment will not work. Here, KRAS is linked to adenocarcinoma.